Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?

To: Cary C who wrote (18203)	1/5/2000 8:56:00 PM
From: Amigo Mike	Read Replies (1) \| Respond to of 29382

Hi Amigo, Hope all is well with you and yours ..... Happy New Year ! NABI looks like it is forming an uptrend. This one was as high as $14 couple years ago. Seems to have a couple nice products too. Hmmmmmmmmm ........... this one could be a nice play assuming there is some reallocation of cash into bios. Have to watch this one. Good Insider ownership, nice institutional ownership also. Appears to be a slow mover though. Amigo Mike

To: Cary C who wrote (18203)	1/9/2000 1:24:00 PM
From: Sergio H	Read Replies (1) \| Respond to of 29382

Cary, on your rec. I took a good look at NABI. I can see why you are enthustiastic about this stock. Earnings report is expected next week and NABI has stepped up, turning in a healthy profit for the year. They have three drugs currently being marketed. The most profitable being NABI-HB. <Hepatitis B is the most severe form of viral hepatitis and the leading cause of liver cancer. One hundred times more infectious than the AIDS virus, it is the ninth leading cause of death worldwide. It is estimated that 350 million people worldwide are chronically infected with HBV, one-third of whom are expected to develop serious liver disease and approximately 1 million will die each year. At-risk individuals include healthcare workers, neonates born to HBV-positive mothers and sexually active individuals with multiple partners.> The pipeline is full of promising projects including at least two drugs in late stage FDA approval testing, not to mention the potential of NABI's Nicotine Vaccine. Company has excellent marketing connections and they are stepping up their manufacturing ability. Mutual funds, Institutions and Insiders have been accumulating this stock and the sector seems to be at an early point of a rally. Without going into details,the technical picture on NABI is clearly solid as are the fundamentals. Nice pick. Are you in? Sergio